17/08/2023
While pricing controls imposed by the Inflation Reduction Act of 2022 (IRS) may appear positive for patients in the short term, and is considered a step forward in improving affordability of, and access to, innovative medical treatments, these controls may have unintended consequences on biopharmaceutical drug development programs and investments in the long term unless this pressure is offset by the opportunity to modernize the way clinical trials are conducted.
The Inflation Reduction Act of 2022 (IRA) covers new and reinstated tax laws that will affect individuals and businesses. Through IRA, President Biden delivered on his promise to lower prescription drug costs by allowing, for the first time, the U.S. Centers for Medicare & Medicaid Services (CMS) to...
